Apnimed will showcase recent data on its investigational oral obstructive sleep apnea (OSA) drug, AD109, at World Sleep 2023.
AD109 (aroxybutynin/atomoxetine) is a potential first-in-class, novel pharmacologic that is specifically designed to target the key neurological pathways in OSA that activate upper airway dilator muscles to maintain an open airway during sleep. It is currently in phase 3 clinical trials.
“People with obstructive sleep apnea from around the world need a safe and effective oral medication that can be taken at bedtime to address the underlying biology of the disorder,” says Larry Miller, MD, CEO of Apnimed, in a release. “We are excited to share the latest data on our lead investigational candidate AD109 and discuss how this potential novel pharmacologic therapy may help people with mild, moderate, and severe OSA.”
AD109 has been granted Fast Track designation by the FDA
Symposium: Clinical trials in sleep–disordered breathing: What have we learned and where do we go from here?
Presentation: Pharmacologic approaches to treatment of obstructive sleep apnea
Time: Tuesday, Oct 24, from 11:35-11:51 am BRT
Location: Room 24, Windsor Convention & Expo Center
Presenter: Luigi Taranto Montemurro, MD, Chief Scientific Officer, Apnimed